RxDoctor Payments Data

Jordana Fein

Retina Specialist · Manassas, VANPI 1841463098

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $267,314 of the $411,601 with a category attached, or 64.9%. 23 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 51.6% of the total. Among retina specialist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$411,601in general payments, 2019–2025

Across 434 payments — averaging $948.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$212K
  • Apellis Pharmaceuticals, Inc.$119K
  • Genentech USA, Inc.$52K
  • Regeneron$11K
  • Harrow Eye, LLC$6K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
  • plus $7K from 17 others
$1,507,896in research payments, 2019–2025

Across 618 payments — averaging $2439.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Apellis Pharmaceuticals, Inc.$431K
  • Bayer$377K
  • Regeneron$315K
  • AstraZeneca$219K
  • Ocular Therapeutix, Inc.$111K
  • Kyowa Kirin, Inc.$55K
  • plus $840 from 1 others

What the payments were for

  • Consulting fees$107,25226%
  • Speaking & faculty fees$267,31465%
  • Travel & lodging$25,9576%
  • Food & beverage$11,0783%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411,601 in reported general payments places this provider in the 95th percentile of 41 retina specialist providers in Virginia.

See all retina specialist providers in Virginia

Medicare billing

Part B allowed, 2024
$6,129,926
Medicare patients
1,173
Services billed
47,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate52$2,126
Ofloxacin28$376
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$217
Latanoprost21$174
Timolol Maleate18$49

Paid to pharmacies, not to this prescriber.

Other retina specialist in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →